The focus of the Molecular and Genomic Pathology Division is to provide Weill Cornell Medicine physicians with molecular information that will facilitate the diagnosis of diseases, monitor the prognosis of the patients and assist in the selection of appropriate therapeutic options. Our state-of-the-art facility uses innovative genomic technologies to interrogate and identify disease related entities in solid tumors, hematologic malignancies, infectious diseases and inherited diseases. Working closely with our clinicians, our mission is to provide molecular testing of the highest quality with a direct impact on patient care.
The Division of Molecular and Genomic Pathology at New York Presbyterian-Weill Cornell Medicine is comprised of two main entities: The Molecular Pathology and Molecular Hematopathology Laboratories, both of which are CLIA-certified and accredited by New York State Department of Health (NYSDOH) and the College of American Pathologists (CAP).
The Molecular Pathology Laboratory offers molecular pathology services, in infectious disease, transplant, genetics and solid tumor, including a NYSDOH-approved 50-gene panel next-generation sequencing test for identification of mutations in cancer.
The Molecular Hematopathology Laboratory performs molecular-based tests to aid in the diagnosis and management of hematologic cancers and offers expert consultation in specialized molecular testing for hematopathologists and clinical hematologists. The primary goal of the laboratory is to provide accurate molecular diagnostic information using modern technology to facilitate the delivery of excellent personalized health care to patients inflicted with hematologic malgnancies. The laboratory is co-directed by Wayne Tam, MD, PhD and Michael Kluk, MD, PhD.
The Englander Institute for Precision Medicine (IPM) at Weill Cornell Medicine and NewYork-Presbyterian Hospital is a translational research hub. The IPM team of physician-scientists are directing their collective expertise and wealth of knowledge to pinpoint the molecular underpinnings of disease and spur the discovery of novel therapies. The Division of Molecular and Genomic Pathology works in close collaboration with the IPM.